Araris Biotech AG

Araris Biotech AG

  • Samsung Ventures invests in Araris

  • Proceeds will be used to support the further development and advancement of Araris’ antibody-drug conjugate (ADC) candidates.

AU ZH, Switzerland, April 11, 2023 (GLOBE NEWSWIRE) — Araris Biotech AG (“Araris” or “the Company”), a pioneer in proprietary antibody-drug conjugate (ADC)-linker technology, announced today that Samsung Venture Investment Corporation (“Samsung Ventures”), an investment corporation established to promote the development of new technologies, has invested in the company in an independent deal ahead of its ongoing Series A funding.

The investment is made through Samsung Life Science Fund – jointly created between Samsung Biologics (KRX: 207940.KS) and Samsung C&T, and managed by Samsung Ventures – which reflects Samsung’s commitment to further explore and expand various business opportunities in biopharmaceuticals.

Araris Biotech is a pioneer in proprietary antibody-drug conjugate (ADC)-linker technology, where its linker platform enables payload attachment to off-the-shelf antibodies without the need to re-engineer or dilute the antibodies, resulting in highly homogeneous, stable and potent ADCs. Treatment in a cost and time effective manner. It also has the potential to address challenges associated with ADCs, including solubility and unstable linkage issues.

The latest investment reflects Samsung’s commitment to further expand its pipeline. Samsung, as a strategic investor, will collaborate with Araris to evaluate, manufacture and develop assets using the company’s proprietary ADC technology in close collaboration with Samsung affiliates involved in the discovery and development, and manufacturing of novel biologics.

“Araris has the potential to develop best-in-class ADC therapies, and we see room for collaboration in the creation and development of new drugs,” said John Rim, CEO of Samsung Biologics.

“We are pleased to receive this support from Samsung, as well as to recognize the potential of our linker-payload toolbox and conjugation technology in such a rapidly growing ADC field,” said Philip Speicher, PhD, Chief Executive Officer. and co-founder of Araris Biotech. “We look forward to using these proceeds to further support our efforts to advance our ADC candidates toward the clinic.”

About Araris Biotech AG

Araris Biotech AG is pioneering the development of its novel antibody-drug conjugate (ADC)-linker technology that enables efficient and precise production of ADCs. Its linker platform enables attachment of any drug payload to ‘off the shelf’ antibodies, without the need for prior antibody engineering. The resulting ADCs have shown much higher activity at lower doses and improved therapeutic index compared to many FDA-approved ADCs. Araris is a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich.

For more information, please visit www.ararisbiotech.com or follow Araris on Twitter and LinkedIn.

Corporate Contact:

Philip Speicher, Ph.D.
Chief Executive Officer
[email protected]

Media Contact:

Veronica Ames
LifeSci Communications, LLC
[email protected]

About Samsung Ventures

Samsung Venture Investment Corporation was established to promote small and medium-sized companies involved in the development of new technologies. Our collaboration is based on managerial know-how and trust, and is actively investing in future-oriented businesses based on new and innovative technologies that are expected to serve as new growth engines. For more details please visit our website; https://www.samsungventure.co.kr/english_main.do.

By admin

Leave a Reply

Your email address will not be published. Required fields are marked *